Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 8 | 2020 | 206 | 2.100 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2020 | 629 | 1.670 |
Why?
|
| Head and Neck Neoplasms | 7 | 2021 | 561 | 1.520 |
Why?
|
| Peripheral Nerves | 2 | 2021 | 22 | 1.300 |
Why?
|
| Mouth Mucosa | 7 | 2011 | 51 | 1.290 |
Why?
|
| Gingival Neoplasms | 4 | 2011 | 13 | 1.250 |
Why?
|
| Neoplasm Invasiveness | 4 | 2021 | 369 | 0.920 |
Why?
|
| Neurilemmoma | 2 | 2020 | 26 | 0.920 |
Why?
|
| Diagnosis, Differential | 15 | 2014 | 1140 | 0.840 |
Why?
|
| Jaw Diseases | 2 | 2014 | 7 | 0.800 |
Why?
|
| Pathology, Surgical | 2 | 2021 | 4 | 0.740 |
Why?
|
| Rhabdomyosarcoma | 2 | 2012 | 36 | 0.710 |
Why?
|
| Mucocele | 2 | 2010 | 20 | 0.710 |
Why?
|
| Gingival Diseases | 3 | 2008 | 22 | 0.640 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 800 | 0.640 |
Why?
|
| Oral Ulcer | 3 | 2007 | 22 | 0.600 |
Why?
|
| Mandibular Neoplasms | 3 | 2011 | 16 | 0.590 |
Why?
|
| Odontogenic Cysts | 3 | 2007 | 13 | 0.570 |
Why?
|
| Mouth Diseases | 4 | 2010 | 39 | 0.560 |
Why?
|
| Osteoblastoma | 1 | 2014 | 1 | 0.500 |
Why?
|
| Osteoma, Osteoid | 1 | 2014 | 5 | 0.500 |
Why?
|
| Jaw Neoplasms | 1 | 2014 | 4 | 0.500 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 7 | 0.490 |
Why?
|
| Sarcoma, Ewing | 1 | 2014 | 26 | 0.490 |
Why?
|
| Mucous Membrane | 1 | 2014 | 66 | 0.480 |
Why?
|
| Osteosarcoma | 1 | 2014 | 35 | 0.480 |
Why?
|
| Humans | 43 | 2021 | 68618 | 0.470 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 94 | 0.470 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2014 | 40 | 0.470 |
Why?
|
| Fibroma | 2 | 2011 | 20 | 0.460 |
Why?
|
| Adult | 17 | 2021 | 21403 | 0.460 |
Why?
|
| Lip Diseases | 2 | 2010 | 8 | 0.440 |
Why?
|
| Female | 23 | 2021 | 38074 | 0.430 |
Why?
|
| Maxillary Neoplasms | 1 | 2012 | 12 | 0.420 |
Why?
|
| Epithelial Cells | 1 | 2014 | 431 | 0.400 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 4848 | 0.400 |
Why?
|
| Sebaceous Glands | 2 | 2010 | 8 | 0.390 |
Why?
|
| Lip Neoplasms | 1 | 2011 | 12 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 47 | 0.390 |
Why?
|
| Vascular Neoplasms | 1 | 2011 | 15 | 0.390 |
Why?
|
| Tongue Diseases | 2 | 2010 | 14 | 0.390 |
Why?
|
| Fasciitis | 1 | 2011 | 30 | 0.390 |
Why?
|
| Precancerous Conditions | 4 | 2020 | 74 | 0.380 |
Why?
|
| Tooth Erosion | 1 | 2010 | 5 | 0.380 |
Why?
|
| Bulimia | 1 | 2010 | 72 | 0.370 |
Why?
|
| Mandibular Diseases | 2 | 2007 | 28 | 0.360 |
Why?
|
| Periodontal Diseases | 1 | 2010 | 54 | 0.360 |
Why?
|
| Middle Aged | 13 | 2021 | 21147 | 0.350 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 122 | 0.350 |
Why?
|
| Lip | 1 | 2009 | 12 | 0.350 |
Why?
|
| Choristoma | 1 | 2010 | 20 | 0.350 |
Why?
|
| Male | 19 | 2021 | 37321 | 0.350 |
Why?
|
| Benzo(a)pyrene | 1 | 2009 | 7 | 0.340 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 11 | 0.340 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 14 | 0.340 |
Why?
|
| Palate, Hard | 2 | 2006 | 7 | 0.340 |
Why?
|
| Palatal Neoplasms | 2 | 2006 | 10 | 0.340 |
Why?
|
| Plasminogen | 1 | 2008 | 28 | 0.320 |
Why?
|
| Genital Diseases, Female | 1 | 2008 | 23 | 0.320 |
Why?
|
| Peritoneum | 1 | 2008 | 27 | 0.310 |
Why?
|
| Skin Diseases | 1 | 2010 | 122 | 0.310 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 30 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 318 | 0.310 |
Why?
|
| Jaw Cysts | 1 | 2007 | 2 | 0.310 |
Why?
|
| Observer Variation | 2 | 2021 | 330 | 0.300 |
Why?
|
| Aged | 10 | 2021 | 14862 | 0.300 |
Why?
|
| Leukoplakia, Oral | 1 | 2007 | 12 | 0.290 |
Why?
|
| Alveolar Process | 1 | 2007 | 18 | 0.290 |
Why?
|
| Pemphigus | 1 | 2006 | 12 | 0.270 |
Why?
|
| Adolescent | 8 | 2020 | 8912 | 0.270 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 3 | 0.270 |
Why?
|
| Carcinoma in Situ | 2 | 2020 | 47 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 756 | 0.240 |
Why?
|
| Biopsy | 4 | 2018 | 540 | 0.220 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 100 | 0.210 |
Why?
|
| Maxillary Diseases | 3 | 2007 | 13 | 0.210 |
Why?
|
| Inflammation | 1 | 2008 | 1030 | 0.200 |
Why?
|
| Hyalin | 2 | 2012 | 8 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2800 | 0.180 |
Why?
|
| Metaplasia | 2 | 2010 | 27 | 0.180 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2020 | 9 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 21 | 0.180 |
Why?
|
| Young Adult | 5 | 2018 | 5717 | 0.180 |
Why?
|
| Monocytes | 1 | 2020 | 210 | 0.160 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 29 | 0.160 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2018 | 14 | 0.160 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 33 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1173 | 0.150 |
Why?
|
| Parotid Neoplasms | 1 | 2018 | 49 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 499 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2020 | 1174 | 0.140 |
Why?
|
| Child | 3 | 2014 | 6405 | 0.140 |
Why?
|
| Pathologists | 1 | 2016 | 10 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2018 | 7277 | 0.140 |
Why?
|
| Erythroplasia | 2 | 2006 | 6 | 0.130 |
Why?
|
| Radiography | 3 | 2007 | 572 | 0.130 |
Why?
|
| Mouth | 2 | 2018 | 64 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 622 | 0.130 |
Why?
|
| Morbidity | 1 | 2015 | 130 | 0.120 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2014 | 10 | 0.120 |
Why?
|
| Global Health | 1 | 2015 | 136 | 0.120 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2014 | 12 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2014 | 14 | 0.120 |
Why?
|
| Cartilage | 1 | 2014 | 51 | 0.120 |
Why?
|
| Hyperplasia | 1 | 2014 | 89 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 111 | 0.120 |
Why?
|
| Age Factors | 2 | 2010 | 1864 | 0.120 |
Why?
|
| Prognosis | 2 | 2018 | 2093 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2014 | 202 | 0.110 |
Why?
|
| Myogenin | 1 | 2012 | 9 | 0.110 |
Why?
|
| Desmin | 1 | 2012 | 13 | 0.110 |
Why?
|
| Sclerosis | 1 | 2012 | 32 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 215 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 164 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.100 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 6 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 3259 | 0.100 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 41 | 0.100 |
Why?
|
| Vimentin | 1 | 2011 | 47 | 0.100 |
Why?
|
| Ribonucleoproteins | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 10 | 0.100 |
Why?
|
| Neprilysin | 1 | 2011 | 55 | 0.100 |
Why?
|
| Smoking | 3 | 2009 | 1452 | 0.100 |
Why?
|
| Autoantigens | 1 | 2011 | 91 | 0.100 |
Why?
|
| Cell Movement | 2 | 2011 | 630 | 0.090 |
Why?
|
| Cheek | 1 | 2010 | 11 | 0.090 |
Why?
|
| Mouth Floor | 1 | 2010 | 9 | 0.090 |
Why?
|
| Palate | 1 | 2010 | 14 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1465 | 0.090 |
Why?
|
| Color | 1 | 2010 | 50 | 0.090 |
Why?
|
| Rupture | 1 | 2010 | 29 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2010 | 122 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2009 | 5 | 0.090 |
Why?
|
| Hair Follicle | 1 | 2010 | 37 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 1174 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 508 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.080 |
Why?
|
| Molar, Third | 1 | 2007 | 7 | 0.080 |
Why?
|
| Toothache | 1 | 2007 | 7 | 0.080 |
Why?
|
| Tooth Extraction | 1 | 2007 | 27 | 0.080 |
Why?
|
| Georgia | 1 | 2008 | 161 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2008 | 169 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 700 | 0.070 |
Why?
|
| Granular Cell Tumor | 1 | 2007 | 9 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 753 | 0.070 |
Why?
|
| Jaw, Edentulous, Partially | 1 | 2007 | 3 | 0.070 |
Why?
|
| Warts | 1 | 2007 | 6 | 0.070 |
Why?
|
| Keratosis | 1 | 2007 | 17 | 0.070 |
Why?
|
| Erythema | 1 | 2007 | 18 | 0.070 |
Why?
|
| Maxilla | 1 | 2007 | 63 | 0.070 |
Why?
|
| Cysts | 1 | 2007 | 70 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1266 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2006 | 21 | 0.070 |
Why?
|
| Connective Tissue | 1 | 2006 | 61 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 132 | 0.070 |
Why?
|
| Gelsolin | 1 | 2005 | 6 | 0.070 |
Why?
|
| Epithelium | 1 | 2006 | 172 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 29 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 66 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 215 | 0.060 |
Why?
|
| Condiments | 1 | 2005 | 2 | 0.060 |
Why?
|
| Lichen Planus, Oral | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cinnamomum zeylanicum | 1 | 2005 | 3 | 0.060 |
Why?
|
| Candidiasis, Oral | 1 | 2005 | 7 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 102 | 0.060 |
Why?
|
| Erythema Multiforme | 1 | 2005 | 8 | 0.060 |
Why?
|
| Alveolar Bone Loss | 1 | 2005 | 40 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2005 | 237 | 0.060 |
Why?
|
| Incidence | 1 | 2008 | 1603 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 2891 | 0.060 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 805 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 481 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 3187 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 2358 | 0.050 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 10 | 0.040 |
Why?
|
| NADPH Oxidase 2 | 1 | 2020 | 16 | 0.040 |
Why?
|
| NADPH Oxidase 4 | 1 | 2020 | 17 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1667 | 0.040 |
Why?
|
| Tongue | 1 | 2018 | 20 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 213 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 266 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1038 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 446 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2014 | 11 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2014 | 51 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 96 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2673 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 100 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 90 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 137 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 226 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 231 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 284 | 0.030 |
Why?
|
| Risk Factors | 3 | 2007 | 5731 | 0.030 |
Why?
|
| Gene Expression | 1 | 2014 | 770 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 1200 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 73 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 237 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 145 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 274 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2689 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 312 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1641 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 756 | 0.020 |
Why?
|
| Ameloblastoma | 1 | 2006 | 5 | 0.020 |
Why?
|
| Odontogenic Tumors | 1 | 2006 | 9 | 0.020 |
Why?
|
| Mucins | 1 | 2006 | 22 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2007 | 67 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2006 | 35 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2007 | 144 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 306 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 124 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 183 | 0.020 |
Why?
|
| Adenoma | 1 | 2006 | 132 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 397 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 52 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 954 | 0.020 |
Why?
|
| Ceramides | 1 | 2007 | 578 | 0.010 |
Why?
|
| Health Education | 1 | 2005 | 279 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2006 | 617 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 20881 | 0.010 |
Why?
|